Revenue $1.22B, up 9.7% on a year earlier. Companion Animal Group Revenue $1.12B, up 9.4%. CAG Diagnostics Capital Instruments Revenue $47.17M, down 19.5%. Diluted EPS $4.27 against $3.63.
| Q2 FY26 | Q1 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|---|
| Revenue | $1.22B | $1.14B | $1.11B | +9.7% |
| Operating income | $425.57M | $362.59M | $373.05M | +14.1% |
| Net income | $338.41M | $278.45M | $293.99M | +15.1% |
| Diluted EPS | $4.27 | $3.47 | $3.63 | |
| Operating cash flow | $347.16M | $266.25M | $185.74M | +86.9% |
| Capital expenditures | -$24.65M | -$31.98M | -$34.10M | |
| Free cash flow | $322.52M | $234.26M | $151.64M | +112.7% |
| Q2 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|
| Companion Animal Group Revenue | $1.12B | $1.02B | +9.4% |
| CAG Diagnostics Capital Instruments Revenue | $47.17M | $58.60M | -19.5% |
| Organic revenue growth | 9% | 9% | |
| Reference laboratory diagnostic and consulting services revenue | $406.73M | $367.69M | +10.6% |
| CAG organic revenue growth | 8.7% | 10% | |
| Companion Animal Group organic revenue growth | 8.7% | 10% | |
| IDEXX VetLab Consumables Revenue | $375.11M | $375.11M | +0.0% |
| IDEXX VetLab Consumables Revenue Growth | 14.7% | 15% |
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “Idexx Laboratories (IDXX) Q2 FY26 earnings: results and KPIs”, stockatlas.com/companies/IDXX/earnings/2026-q2/, data as of 3 November 2026. Links to this page are welcome.
